



A new German Nuclear Medicine Practice purchases Theraclion Echopulse® system

In total 7 centers offer treatments with Echopulse in Germany

Malakoff – FRANCE, April 4, 2015 – THERACLION (Alternext, FR0010120402 – ALTHE), a company specialized in leading-edge medical equipment for echotherapy, announces today that Nuklearmedizinische Praxis Seeberger, a private nuclear medicine practice in the region of Heilbronn, Germany, has purchased an Echopulse system for the treatment of both, benign thyroid nodules and fibroadenomas of the breast.

The new Nuklearmedizinische Praxis Seeberger, which will open its doors in April, aims to offer a complete and state-of-art set of diagnostics and therapy solutions for thyroid and breast treatments. In this spirit, Dr. Seeberger a leading German Nuclear Medicine specialist in thyroid disease decided to equip his new Center with Echopulse, and thus propose to his patient the only totally non-invasive treatment procedure available on the market.

Dr Seeberger will lead the thyroid program himself and will partner with a senologist for fibroadenoma treatment.

Thanks to Dr Seeberger's high recognition, his patient recruitment area covers a large Southern German region with a strong referral network.

The practice will be the 7th center in Germany to offer treatments with the Echopulse from Theraclion to their patients. 5 out of 7 have started their activity within the last 6 months, showing the fast growing interest for echotherapy.

"I personally believe that the treatment with Echopulse is an answer to the need to replace radioiodine therapy on a long run" says Dr. Seeberger. "It also is a real alternative for patients who can't or don't want to undergo surgery."

Radioiodine therapy is a nuclear medicine therapy for the treatment of certain thyroid diseases, an efficient but cost-intensive method as it requires, in most countries, the hospitalization of the patient due to the usage of radioactive elements. In Germany around 50,000 patients with thyroid disease are treated annually by radioiodine therapy and around 100,000 by surgery.

"Theraclion is proud to partner with Dr Seeberger and to help him to provide echotherapy treatments to his patients. In addition to the already well-identified alternative to surgery market, we see for our technology another opportunity with the foreseeable need to replace in the future radioiodine treatments by solutions that is much easier to implement" adds David Caumartin.



About Theraclion

Theraclion is a French company specializing in high-tech medical equipment using therapeutic ultrasound. Drawing on leading-edge technologies, Theraclion has designed and manufactured an innovative solution for echotherapy, the Echopulse®, allowing non-invasive tumor treatment through ultrasound-guided high-intensity focused ultrasound. Theraclion is ISO 13485 certified and has received the CE mark for non-invasive ablation of breast fibroadenomas and thyroid nodules. Based in Malakoff, near Paris, France Theraclion has brought together a team of 34 people, 50% of whom are dedicated to R&D and clinical trials. For more information, please visit Theraclion's website: www.theraclion.com.

Theraclion is listed on Alternext Paris

PEA-PME eligible

Mnemonic: ALTHE - ISIN Code: FR0010120402



Contact:

Theraclion

David Caumartin
Chief Executive Officer
Tel.: +33 (0)1 55 48 90 70
david.caumartin@theraclion.com

NewCap

Financial Communication and Relations
Emmanuel Huynh / Valentine Brouchet
Tel.: +33 (0)1 44 71 94 94
theraclion@newcap.eu

Kalima

Press Relations
Estelle Reine-Adélaïde / Florence Calba
Tel.: + 33 (0)1 44 90 82 54
era@kalima-rp.fr